The management of non-muscle-invasive bladder cancer (NMIBC) has evolved from the first reports on bladder endoscopy and transurethral resection to the introduction of adjuvant intravesical treatment. However, disease recurrence and progression remain an ongoing risk, placing a heavy burden on healthcare resources and on patients' quality of life. Deeper understanding of the molecular basis of the disease and developments in optics, lasers and computer science are already offering opportunities to revolutionize care and improve long-term prognosis. This article discusses developments likely to cause a paradigm shift towards the delivery of personalized care and reduced burden of disease in NMIBC.
Scandinavian journal of urology. 2017 Feb 07 [Epub ahead of print]
Per-Uno Malmström, Sachin Agrawal, Mats Bläckberg, Peter J Boström, Bernard Malavaud, Dirk Zaak, Gregers G Hermann
a Department of Urology, Division of Surgical Sciences , Uppsala University , Uppsala , Sweden., b Department of Urology, Ashford & St Peter's NHS Trust , St Peter's Hospital , Chertsey , UK., c Department of Urology and Surgery , Helsingborg Hospital , Helsingborg , Sweden., d Department of Urology , Turku University Hospital , Turku , Finland., e Department of Urology , Toulouse Cancer Institute , Toulouse , France., f Department of Urology , Traunstein Hospital , Traunstein , Germany., g Department of Urology , Herlev & Gentofte Hospital, University of Copenhagen , Herlev , Denmark.